Home > News Center > TGA Updates UDI Timeframes Guide to V2.2: Direct Marking Deadlines for EU IVDD Transition Devices

TGA Updates UDI Timeframes Guide to V2.2: Direct Marking Deadlines for EU IVDD Transition Devices

Nov 13, 2026 Regulatory Info 0 views

On November 12, 2026, the Australian Therapeutic Goods Administration (TGA) updated its guidance document ‘Complying with the Unique Device Identification timeframes for medical devices’, revising the version from V2.1 to V2.2.

Official source:

This update mainly corrects inconsistencies in UDI implementation dates during the transition period from the EU IVDD to the IVDR. Based on a comparison between the old and new versions, under the EU IVDD transition arrangements, the direct marking deadline for Class 3 IVDs has been adjusted from the original January 1, 2029 to July 1, 2029, a deferral of 6 months.

1. Key Change: Direct Marking Deadline for Class 3 IVDs Deferred by 6 Months

By comparing version V2.1 with V2.2, the adjustment in this revision is concentrated on the direct marking deadline for Class 3 IVDs under the EU IVDD transition arrangements.

Comparison of dates between the old and new versions:

Compliance requirementV2.1 original dateV2.2 updated dateChange
Class 3 IVD labelling and database submissionJanuary 1, 2029January 1, 2029Unchanged
Class 3 IVD direct markingJanuary 1, 2029July 1, 2029Deferred by 6 months

In other words:

  • The deadlines for UDI labelling and database submission for Class 3 IVDs remain unchanged, still January 1, 2029.
  • The direct marking deadline for Class 3 IVDs has been adjusted from January 1, 2029 to July 1, 2029.
  • This adjustment does not correspondingly defer the obligations for UDI labelling and database submission.

2. Latest UDI Implementation Dates for IVDs of Various Classes under the EU IVDD Transition Arrangements

For IVD products subject to the EU IVDD to IVDR transition arrangements, the UDI implementation dates are as follows:

Product classUDI labelling and UDI record submissionDirect marking and related information updates
Class 4 IVDJuly 1, 2028July 1, 2029
Class 3 IVDJanuary 1, 2029July 1, 2029
Class 2 IVDJanuary 1, 2030July 1, 2030
Class 1 IVDJanuary 1, 2030July 1, 2030

The dates above are the EU IVDD transition arrangement dates as updated in V2.2.

3. Distinguishing Between UDI Labelling and Database Submission and Direct Marking

TGA divides UDI compliance into two main implementation milestones, with manufacturers and Australian sponsors respectively bearing the corresponding responsibilities.

3.1 UDI Labelling and UDI Record Submission

Manufacturers need to:

  • Assign a UDI-DI that meets the requirements of TGA-accepted issuing agencies to the product;
  • Assign a UDI-PI in accordance with the issuing agency’s coding standards;
  • Mark compliant UDIs on the product label and, where applicable, on higher levels of packaging;
  • Provide UDI information on patient implant cards for applicable implantable devices.

The Australian sponsor needs to:

  • Submit UDI records to the Australian UDI database (AusUDID);
  • Link the UDI records with the corresponding Australian Register of Therapeutic Goods entries (ARTG Inclusion);
  • Ensure the submitted data is accurate and kept up to date.

The TGA guidance also stipulates that UDI records should be submitted to AusUDID within 30 days after the product is supplied in Australia.

3.2 Direct Marking

Direct marking mainly applies to devices that meet both of the following conditions:

  • They are reusable;
  • They require reprocessing before use between different patients.

Manufacturers are responsible for directly marking the UDI on applicable devices, while sponsors need to add the direct marking information to the AusUDID records.

Therefore, not all IVD products require physical direct marking. For single-use products, this direct marking requirement does not apply.

4. Recommendations for Medical Device Companies

In light of this TGA guidance update, companies planning to enter or already present in the Australian market are advised to focus on the following:

4.1 Re-verify the UDI timetable applicable to your products

Confirm whether the product falls under the Australian standard UDI implementation arrangements or is a specific product covered by the EU MDD or IVDD transition arrangements, so as to avoid incorrectly applying the transition dates.

4.2 Distinguish between UDI labelling and direct marking obligations

Companies should separately develop plans for label updates, database submission and direct marking, and should not conflate the two implementation milestones.

Grzan

Author:Grzan

Get the latest global medical device development and regulatory news, insights and resources.

WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail